Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel

uniQure Terug naar discussie overzicht

Wat is de waarde van uniQure?

7.836 Posts
Pagina: «« 1 ... 34 35 36 37 38 ... 392 »» | Laatste | Omlaag ↓
  1. forum rang 10 DeZwarteRidder 5 december 2013 15:15
    quote:

    flosz schreef op 5 december 2013 11:45:

    Harald Petry to Speak at Cell & Gene Therapy Feb 20-21, 2014 in San Diego, CA
    This conference is also part of the Future Biotech Summit 2014, which consists of this conference, and two other additional co-located conferences:
    Cell & Gene Therapy
    2nd Orphan Drugs Research & Commercialization
    Ubiquitin Research & Drug Discovery
    www.pr.com/press-release/531322
    Ik heb me eigen direct aangemeld, zo'n interessant congres wil ik niet missen!!
  2. [verwijderd] 5 december 2013 17:23
    quote:

    flosz schreef op 5 december 2013 10:38:

    Laat die leuterkleuter lekker kraaien….
    Begonnen op pagina 1 in juli 2012…ik hoop dat we de vervuiling van dit zoef-draadje kunnen stoppen o.a. door niet meer in te gaan op de braaksels.
    www.iex.nl/Forum/Topic/1286603/uniQur...

    Lesson 1: Remember, BASHERS NEVER BASH A BAD STOCK. Watch the board for stocks with no potential. They never have any bashers. Bashers only go after stocks that are going upwards or have excellent potential to go up. Bashers get left behind, so they want to bring the price down.

    Lesson 2: BASHERS ALWAYS BRING UP OLD NEWS THAT YOU HAVE HEARD MANY TIMES. New startup companies always have a few bits of bad news. The basher will post this over and over again. The stupid basher will try to make the old news a bit fresher to try to fool you.

    Lesson 3: BASHERS POST MANY TIMES A DAY. They try to wear you out. They comment on everything, every other post, and can answer every question. THEY KNOW IT ALL! There is no positive comment they won't bash. They try to control the board. True longs may have to address the bashers or they will appear to the newbies as being the people with all the information.

    Lesson 4: BASHERS WILL LIE TO YOUR FACE. Never trust a basher. The truth on startup companies is that many mistakes are made and losses happen. The basher will try to make you believe all startup companies make a profit, release financials every quarter and all aspects of the business run smoothly. THIS IS NOT TRUE. THE BASHERS LIE TO YOU. Startup companies can go years without profits, financials and good business, this is the nature of the beast.

    Lesson 5: The bashers know YOU CAN'T VERIFY THEIR STATEMENTS. That's why they make the statements they do.

    Lesson 6: The bashers PLAY ON YOUR LACK OF KNOWLEDGE. They can lie about information and you couldn't know the difference (unless you have done your assessment of the company and know the truth and facts).

    Lesson 7: Bashers play on your lack of patience. YOU have held a penny stock for a while. You knew it will be a big penny stock someday, but the BASHER CAN GET TO YOU BECAUSE YOU ARE TIRED OF WAITING FOR YOUR GAIN . That's when the basher is best. You are tired. You have forgotten the goal for the penny stock was to hold it for one year. The basher is bothersome, so you dump it on a bad day. Some others also dump. Then you get mad for your loss and return to let everyone know how mad you are. Then you turn into a basher as well. THE BASHER HAS WON, AND GAINED A NEW PARTNER TOO, to be able to get in at a great price.

    Lesson 8: BRING THE PRICE DOWN. That is the basher's job. The truth is not important. Lies are the norm. Post continuously on the board every day. They are trying to hit the newbies visiting the board. They are trying to wear out the longs on the board. They do whatever it takes to wear the longs out.

    Lesson 9: BASHERS WILL TRY TO CREATE DOUBT AND GET YOU TO RESEARCH ITEMS THAT THEY KNOW WILL LEAD TO THE CREATION OF DOUBT IN YOU AND IN OTHER STOCKHOLDERS. A typical trick of an advanced basher is to propose that there is a potential "problem" because "we" don't have the facts on a particular subject. The basher dares someone in the group to find out the answer to the question. The basher already knows the answer; the basher already knows what will be found. The power of this tactic is that the basher is now in control of the actions of the stockholders; the basher has you, the stockholder doing HIS/HER due diligence and when you, the stockholder come back to the group with a questionable finding then the basher gains credibility. What to do??? Solution??? Well, I think it's important to find answers but on your own terms. I actually pick up the phone and call the company and talk to the investor relations person or the CEO until I get a satisfactory answer. The problem here is that the advanced basher has you doing his bidding and his work; you have essentially joined his ranks. So, develop your own little Due Diligence package and answer questions by placing the information into the package and referring all new investors to read the answers to questions raised in the Investor Information package but DON'T GET INTO A CONVERSATION WITH THE BASHER REGARDING THE TOPIC. THAT IS WHERE YOU LOSE. DON'T CONVERSE WITH THE BASHER; ANSWER INDIRECTLY; DON'T USE THE BASHERS NAME; DON'T GET INTO A PERSONALITY CONTEST.

    www.youtube.com/watch?v=xu9Ggjw6aBk

    een score van 9 uit 9...kan niet missen...scoorde UniQures kansen maar zo hoog!

    De geschiedenis herhaalt zich steeds opnieuw. Op het Crucell-forum indertijd, was het ook schering en inslag. Een enkeling had de moed om langs te komen op een borrel toen...kijk, dat waardeer ik. Een andere mening is welkom en moet mij/ons scherp houden, maar dit gaat niet meer om een andere mening.
  3. Prof. Dollar 6 december 2013 17:44
    quote:

    Antoni schreef op 6 december 2013 16:41:

    De site is volgens mij vernieuwd. Het onderwerp Clinical programs is nu wat duidelijker. Hemophilia B gaat verder 2e halfjaar 2014.

    www.uniqure.com/pipeline/clinical-pro...
    De site in inderdaad bijgewerkt.

    Toch valt mij de snelheid van ontwikkeling in de clinical programs een beetje tegen, of men communiceert het karig waardoor een juist beeld van de route en tijd die nog afgelegd moet worden (en de verhouding tot concurrenten) moeilijk op te maken valt.

    Met betrekking tot Hemophilia B had ik eerder een phase II/III verwacht. Blijkbaar kent de phase I/II meerdere stappen: eerst "Phase I/II exploratory clinical trial" en halverwege volgend jaar "Phase I/II dose-escalation clinical trial".

    Hopelijk worden we binnenkort echt positief verrast als bijvoorbeeld het portfolio eens wordt uitbreid met nieuwe programma's, want daar pronkt men steeds mee: platform, modulair, partners.

    2014 kan een interessant jaar worden.
  4. forum rang 10 DeZwarteRidder 6 december 2013 23:17
    quote:

    Prof. Dollar schreef op 6 december 2013 22:55:

    Artikel over het vraagprijsvraagstuk (bespreekt ook uniQure):
    invivoblog.blogspot.nl/2013/12/deals-...
    uniQure BV is the scrappy Dutch biotech that spun out of Amsterdam Molecular Therapeutics BV to win approval for the first gene therapy to be accepted by regulators in the major world markets. After several false starts and near-death experiences, Glybera (alipogene tiparvovec) got EU approval in November 2012 for the ultra-orphan disease lipoprotein lipase deficiency. LPD is a childhood genetic disorder in which a protein needed to metabolize fat molecules is missing, causing a large amount of fat to build up in the blood.

    The company has partnered commercial rights covering Europe and selected major emerging markets for Glybera and a mid-stage hemophilia B gene therapy to Italy’s Chiesi Farmaceutici SPA. It has forged ahead with building U.S.-based manufacturing capacity, particularly in advance of an FDA filing for Glybera pending ongoing discussions with the agency. It has hired a CEO and preliminary staffing for its Boston-based U.S. operations, to build out clinical, regulatory, and commercial infrastructure. It’s busy planning launch strategy, identifying patients, and meeting with payers.

    But there’s a problem. We asked uniQure’s CEO, Jörn Aldag, how he planned to price his gene therapies. Our discussion focused on the hemophilia B treatment, next in line for approval. Aldag noted that, unlike the long-acting factors being readied for market by Biogen Inc. and others, where patients may be able to infuse every other week, “we’re offering a one-shot treatment. The patient would not have to come back to the hospital for many, many years.”

    Aldag said ten patients in the first hemophilia B Phase I/II trial, still ongoing at St. Jude Hospital in Memphis, TN, have been treated and required no or significantly reduced prophylactic treatment for up to three years.

    This is truly wondrous news for patients with hemophilia B. The issue is that each gene therapy carries an unknown duration of effect. Will those patients enrolled in the St. Jude trial require a booster next week? Or will they continue for another 3 years, 10 years, indefinitely?

    Aldag is grappling with the same issue with Glybera, and now Chiesi is weighing in on the discussions. The options they’re considering boil down to whether to ask for a front-loaded “down payment, or do we ask for annuity payments,” says Aldag, describing a system of payments over time. He allows that the pricing paradigm will change when he moves beyond orphan monogenic diseases, for instance, into larger-population neurodegenerative disorders, such as Parkinson’s disease (uniQure has a Parkinson’s gene therapy which is currently in Phase I/II). “Those would not command as high a price.”
  5. Prof. Dollar 7 december 2013 11:12
    quote:

    Antoni schreef op 7 december 2013 10:44:

    Het nieuws van de filing staat er niet meer op. Vergeten?
    Vreemd. Ook omdat eerdere en latere persberichten van uniQure er wel op staan.

    Dit was de direct link:
    www.uniqure.com/news/184/182/uniQure-...

    Het enige wat me toen opviel is dat het een voorgeschreven persbericht was; andere IPO-kandidaten gebruikten exact dezelfde tekst, met enig verschil de genoemde bedrijfsnaam.
  6. forum rang 10 DeZwarteRidder 7 december 2013 11:34
    quote:

    Prof. Dollar schreef op 7 december 2013 11:12:

    [...]
    Vreemd. Ook omdat eerdere en latere persberichten van uniQure er wel op staan.
    Dit was de direct link:
    www.uniqure.com/news/184/182/uniQure-...
    Het enige wat me toen opviel is dat het een voorgeschreven persbericht was; andere IPO-kandidaten gebruikten exact dezelfde tekst, met enig verschil de genoemde bedrijfsnaam.
    Het bericht was dus een vergissing...!!
  7. Prof. Dollar 7 december 2013 12:27
    quote:

    DeZwarteRidder schreef op 7 december 2013 11:34:

    [...]
    Het bericht was dus een vergissing...!!
    Zou kunnen. Aan de andere kant: certificaathouders worden via de STAK ingelicht, en diens communicatie is gewoon raadpleegbaar via uniqure.com/stak/stak-login.html en NPEX.
  8. forum rang 10 DeZwarteRidder 7 december 2013 22:08
    quote:

    Antoni schreef op 7 december 2013 21:30:

    Ik heb er toch even een e-mail aan gewaagd. Onze vriend zal toch niet gelijk krijgen...
    Natuurlijk heb ik gelijk......!!
  9. [verwijderd] 9 december 2013 10:27
    Dear Anton van der Sloot,

    This is to inform you that the F-1 filing article is now visible again on our website.

    Last week there has been some maintenance to our website. Unfortunately, due to errors, the F-1 filing article was accidentally removed.

    Please find attached a copy of the F-1 Filing article and our sincere apologies for the inconvenience.



    Kind regards,



    Marsha Lemmers

    Administrative Assistant

    uniQure B.V.


  10. QLVT 11 december 2013 21:04
    Ja ja geen nieuws geen speculaties,
    ik denk dat we moeten wachten op
    20 februari 2014,en dan maar hopen
    op goed nieuws en een evt ipo op den duur
    wat onze forum site betreft zal het
    wel heel rustig blijven de komende
    tijd
    Tegen kerst zullen elkaar nog wel
    de beste wensen doen...
  11. Prof. Dollar 18 december 2013 19:55
    Het laatste bericht van uniQure had betrekking tot Sanfilippo B:
    www.uniqure.com/news/182/182/Clinical...

    Bij gebrek aan direct nieuws, een update met betrekking tot het bredere veld:
    "Abeona Therapeutics, a Cleveland-based biotech startup, said it closed $750,000 in seed financing to complete preclinical development of therapies for children with Sanfilippo Syndrome, a rare terminal genetic disorder that kills afflicted children before they reach their mid-teens. With this funding, more than $2 million has been raised to date for this initiative."

    abeonatherapeutics.com/wp-content/upl... (PDF)
7.836 Posts
Pagina: «« 1 ... 34 35 36 37 38 ... 392 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.156
AB InBev 2 5.544
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.458
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.927
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 193
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.887
Aedifica 3 927
Aegon 3.258 323.198
AFC Ajax 538 7.092
Affimed NV 2 6.306
ageas 5.844 109.908
Agfa-Gevaert 14 2.074
Ahold 3.538 74.357
Air France - KLM 1.025 35.320
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.057
Alfen 16 25.467
Allfunds Group 4 1.523
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 426
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 244.225
AMG 972 134.699
AMS 3 73
Amsterdam Commodities 305 6.753
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 501
Antonov 22.632 153.605
Aperam 92 15.102
Apollo Alternative Assets 1 17
Apple 5 387
Arcadis 252 8.808
Arcelor Mittal 2.035 321.073
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.373
Aroundtown SA 1 221
Arrowhead Research 5 9.752
Ascencio 1 30
ASIT biotech 2 697
ASMI 4.108 39.688
ASML 1.767 111.974
ASR Nederland 21 4.522
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 14.304
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.462

Macro & Bedrijfsagenda

  1. 10 april

    1. Consumenten- en producentenprijzen, maart (Chi)
    2. Industriële productie, februari (NL)
    3. Fagron cijfers eerste kwartaal en beleggersdag
    4. Aalberts jaarvergadering
    5. Van Lanschot Kempen bava (kapitaalteruggave)
    6. Inflatie, maart (VS) volitaliteit verwacht
    7. Steunaanvragen - wekelijks (VS)
    8. TSMC, omzetcijfers maart
  2. 11 april

    1. Faillissementen, maart (NL)
    2. Inflatie, maart (Dld)
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht